Trials for which samples have been obtained through TrialNet

Completed studies

1. Mycophenolate Mofetil and Daclizumab in New Onset Type 1 Diabetes;  
2. Mixed Meal Tolerance Test versus Glucagon Stimulation Tests  
3. Validation and Reproducibility of Islet Reactivity by T cell assays in Type 1 Diabetes  
4. Rituximab in New Onset type 1 diabetes  
5. Abatacept in New Onset Type 1 diabetes  
6. GAD vaccination in new onset type 1 diabetes  
7. Meticulous Metabolic control in new onset type 1 diabetes  
8. Canakinumab in new onset type 1 diabetes  
9. Nutritional Intervention to Prevention Diabetes in genetically at risk newborns  

Ongoing Studies

1. TN01: TrialNet Pathway to Prevention.  
   a. Natural history study of antibody positive individuals
2. TN07: TrialNet Oral Insulin Prevention Study  
   a. Placebo controlled randomized trial of 7.5 mg daily oral insulin to prevent diabetes onset in antibody positive individuals with normal glucose tolerance
3. TN10: TrialNet Anti-CD3 Prevention Study  
   a. Placebo controlled randomized trial of one 14 day course of Teplizumab to prevent diabetes onset in antibody positive individuals with abnormal glucose tolerance.
4. TN16: Long Term Follow-Up  
   a. Natural history study of individuals previously followed in TN01 or other TrialNet clinical trials pre or post clinical diagnosis.
5. TN18: Abatacept Prevention Study  
   a. Placebo controlled randomized trial of one year treatment of Abatacept to prevent abnormal glucose tolerance in antibody positive individuals with normal glucose tolerance.
6. TN19: ATG/GCSF Study
Trials for which samples have been obtained through TrialNet

a. Three arm, placebo controlled randomized trial of one course of ATG with or without six week course of GCSF to preserve beta cell function in newly diagnosed individuals with T1D.

7. TN20: Immune effects of Oral Insulin
   a. Randomized trial of 65.5 mg daily or 500 mg every other week of oral insulin in antibody positive individuals to determine immune effects of treatment.